Pregnant outcomes of critically ill pregnant patients with pulmonary hypertension: A multicenter retrospective study

Lin Zhang¹, Guoqiang Qie¹, Xiaoyu Yin¹, Hongyan Zhao², Fusen Zhang³, Tao Wang¹, Mei Meng⁵, Jing Sha¹ and Yufeng Chu¹†

¹Department of Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, ²Department of Critical Care Medicine, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China, ³Department of Intensive Care Unit, Taifan Central Hospital, Taian, China, ⁴Department of Intensive Care Unit, Zhinhu Medical University Hospital, Binzhou, China, ⁵Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Objective: To identify the pregnancy outcomes and risk factors of critically ill pulmonary hypertension (PH) patients with intensive care unit (ICU) admission.

Methods: The multicenter, retrospective cohort study was performed on 60,306 parturients from January 2013 to December 2018 in China. Diagnosis of PH was based on the estimation of systolic pulmonary arterial pressure (sPAP) via echocardiography. Patients were stratified by sPAP into three groups, mild (30–50 mmHg), moderate (51–70 mmHg), and severe (≥70 mmHg). The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of in-hospital death, heart failure, and sustained arrhythmias requiring treatment. The secondary outcome was fetal adverse clinical events (FACE), a composite of fetal/neonatal death, prematurity, small birth weight, and fetal distress.

Results: A total of 181 pregnant patients were enrolled, including 101 patients with mild PH, 31 with moderate PH, and 49 with severe PH. The maternal median age was 32 (27, 35) years and 37% were nulliparous. The MACE occurred in 59 (59/181, 32.6%) women, including in-hospital death in 13 (13/181, 7.2%), heart failure in 53 (53/181, 29.3%), and sustained arrhythmias in 7 (7/181, 3.9%). The incidence of FACE was as high as 66.3% (120/181). Compared with mild and moderate PH patients, patients with severe PH had a significantly higher mortality rate (22.4 vs. 1.51%, P < 0.001) and MACE incidence (51.0 vs. 25.8%, P = 0.001). Although the incidence of FACE in severe PH was slightly higher than that in mild to moderate PH, there was no significant difference (69.4 vs. 65.1%, P = 0.724). PH complicated with left heart disease (OR = 4.365; CI: 1.306–14.591), elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) level (OR = 1.051; CI: 1.015–1.088), and sPAP level estimated by echocardiography (OR = 1.021; CI: 1.003–1.040) were independently associated with MACE in multivariable regression (P < 0.05). Increased risk of FACE was noted for PH patients combined with eclampsia/preeclampsia (OR = 6.713; CI: 1.806–24.959).
Conclusion: The incidence of MACE and FACE remained high in critically ill pregnant patients with PH, particularly moderate and severe PH in China. Further studies are warranted to identify subsets of women with PH at lower pregnant risks and seek more effective therapy to improve pregnancy outcomes.

KEYWORDS
pulmonary hypertension, pregnancy, pregnant outcomes, critical care, China
Study population and process of inclusion. ICU, intensive care unit; PH, pulmonary hypertension.

Diagnostic criteria and definitions of clinical parameters

Diagnosis of PH was based on the estimation of systolic pulmonary arterial pressure (sPAP) via echocardiography. When patients were admitted, echocardiography was performed by a qualified sonographer as described in the 2015 ESC/ERS guideline (3). Patients were stratified by sPAP into three groups, mild (30–50 mmHg), moderate (51–70 mmHg), and severe (>70 mmHg) (2). In addition, patients were divided into four groups according to the related disease: iPH, patients with an initial diagnosis of idiopathic PH before this admission and without any known cause of PH; CHD-PH, patients with a previous history of congenital heart disease; LHD-PH, patients with a history of left ventricular systolic dysfunction caused by valvular disease, cardiomyopathy, or acquired left heart outflow tract obstruction, but not congenital structural abnormality; oPH, PH caused by other diseases. For more definitions see Supplementary material 1.

Outcomes

The primary outcome was MACE, defined as a composite of in-hospital death, heart failure, and sustained arrhythmias requiring treatment (4, 7). The secondary outcome was FACE, a composite of fetal/neonatal death, prematurity, small birth weight, and fetal distress (8).

Ethical approval

Given the retrospective design of the study, which was based on data extracted from the electronic medical system, written informed consent was not required. All the procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was registered in the Chinese Clinical Trial Registry and was approved by the Ethics Committee of Shandong Provincial Hospital (Registration number: ChiCTR1900020624).

Statistical analysis

The distributions of variables were examined with Kolmogorov-Smirnov tests. Continuous data were expressed as mean ± standard deviation or medians (interquartile range, IQR) as appropriate. Groups were compared by student t-tests or ANOVA analysis if they obey a normal distribution. If not, they were compared by Mann-Whitney U-tests or Kruskal-Wallis tests. Categorical data were expressed as numbers (percentages) and were compared by the chi-square test or
### TABLE 1 Baseline characteristics of pregnant women based on PH severity diagnosed via echocardiography.

| Variable                              | Total \( (n = 181) \) | Mild PH \( (n = 101) \) | Moderate PH \( (n = 31) \) | Severe PH \( (n = 49) \) | \( p \)-value |
|---------------------------------------|------------------------|--------------------------|---------------------------|--------------------------|--------------|
| Age, years [M, (Q1, Q3)]             | 32 (27, 35)            | 29 (33, 37)              | 26 (31, 37)               | 24 (30, 34)              | 0.014        |
| \( \leq 25 \) y (n, %)               | 34 (18.8)              | 13 (12.9)                | 4 (12.9)                  | 17 (34.7)                |              |
| 25-35 y (n, %)                       | 92 (50.9)              | 51 (50.5)                | 17 (54.8)                 | 24 (49.0)                |              |
| \( \geq 35 \) y (n, %)               | 55 (30.4)              | 37 (36.6)                | 10 (32.3)                 | 8 (16.3)                 |              |
| Nulliparous (n, %)                   | 67 (37.0)              | 32 (31.7)                | 11 (35.5)                 | 24 (49.0)                | 0.081        |
| BMI, kg/m\(^2\)                      | 26.8 (23.8, 30.9)      | 28.2 (25.0, 32.6)        | 26.5 (23.8, 29.6)         | 24.8 (22.4, 27.7)        | 0.000        |
| Diagnosis made (n, %)                |                        |                          |                           |                          | 0.096        |
| Before pregnancy                     | 120 (66.3)             | 60 (58.6)                | 24 (77.4)                 | 36 (73.5)                |              |
| During pregnancy                     | 61 (33.7)              | 41 (40.6)                | 7 (22.6)                  | 13 (26.5)                |              |
| Treatment (n, %)                     |                        |                          |                           |                          |              |
| Targeted PH therapy                  | 0 (0)                  | 0 (0)                    | 0 (0)                     | 0 (0)                    | NS           |
| Anticoagulation                      | 2 (1.1)                | 1 (1.0)                  | 1 (3.2)                   | 0 (0)                    | 0.452        |
| Gestational week on admission, weeks [M, (Q1, Q3)] | 35 (32, 37)            | 36 (32, 38)              | 36 (33, 38)               | 34 (31, 37)              | 0.112        |
| Saturation, % [M, (Q1, Q3)]          | 100 (98, 100)          | 100 (98, 100)            | 100 (97, 100)             | 100 (98, 100)            | 0.981        |
| MAP, mmHg [M, (Q1, Q3)]              | 92.0 (82.8, 108.8)     | 102.3 (82.8, 117.7)      | 88.7 (80.3, 99.3)         | 89.0 (79.8, 100.3)       | 0.014        |
| Hemoglobin, g/L [M, (Q1, Q3)]        | 114.0 (102.0, 124.0)   | 113.0 (101.0, 119.0)     | 111.0 (102.0, 127.0)      | 116.0 (105.0, 134.0)     | 0.001        |
| Hematocrit, % [M, (Q1, Q3)]          | 35.2 (32.3, 37.7)      | 35.0 (31.8, 36.9)        | 33.8 (32.2, 38.0)         | 35.9 (32.9, 40.8)        | <0.001       |
| Platelets, \( \times 10^9 \)/L [M, (Q1, Q3)] | 193 (146, 230)         | 194.0 (147.0, 218.0)     | 218.0 (175.0, 281.0)      | 219.0                    |              |
| NT-proBNP, pg/ml [M, (Q1, Q3)]       | 490.6 (185.0, 1368.0)  | 424.7 (184.3, 495.4)     | 495.4 (58.4, 595.7)       | 295.1                    | 0.201        |
| Heart failure (n, %)                 | 75 (41.4)              | 27 (26.7)                | 17 (54.8)                 | 31 (63.3)                | <0.001       |
| NYHA class (n, %)                    |                        |                          |                           |                          | <0.001       |
| I                                     | 76 (42.0)              | 53 (52.5)                | 12 (38.7)                 | 11 (22.4)                |              |
| II                                    | 55 (30.4)              | 35 (34.7)                | 10 (32.3)                 | 10 (20.4)                |              |
| III                                   | 36 (19.9)              | 13 (12.9)                | 4 (12.9)                  | 19 (38.8)                |              |
| IV                                    | 14 (7.7)               | 0 (0)                    | 5 (16.1)                  | 9 (18.4)                 |              |
| APACHE II                             | 3 (2.4)                | 3 (2.4)                  | 3 (2.4)                   | 3 (2.5)                  | 0.838        |
| SOFA score [M, (Q1, Q3)]             | 1 (0.2)                | 1 (0.2)                  | 1 (0.2)                   | 1 (0.2)                  | 0.576        |
| Echocardiographic parameters          |                        |                          |                           |                          |              |
| \( sPAP \), mmHg [M, (Q1, Q3)]       | 49.0 (41.0, 73.0)      | 42.0 (38.0, 46.0)        | 58.0 (53.0, 66.0)         | 91.0 (81.0, 105.0)       | <0.001       |
| Diameter of main PA, cm [M, (Q1, Q3)] | 2.7 (2.4, 3.1)         | 2.7 (2.4, 3.0)           | 3.0 (2.2, 3.2)            | 3.2 (2.5, 3.7)           | 0.075        |
| Complications (n, %)                  |                        |                          |                           |                          |              |
| Hypertension                          | 56 (30.9)              | 44 (43.6)                | 5 (16.1)                  | 7 (14.3)                 | <0.001       |
| Pre-eclampsia/eclampsia               | 49 (27.1)              | 40 (39.6)                | 5 (16.1)                  | 4 (8.2)                  | <0.001       |
| HELLP syndrome                        | 1 (0.6)                | 1 (1.0)                  | 0 (0)                     | 0 (0)                    | NS           |
| Diabetes mellitus                     | 14 (7.7)               | 10 (9.9)                 | 1 (3.2)                   | 3 (6.1)                  | 0.594        |
| Autoimmune disease                    | 11 (6.1)               | 8 (8.9)                  | 0 (0)                     | 3 (6.1)                  | 0.393        |
| Liver damage                          | 5 (2.8)                | 1 (1.0)                  | 2 (6.5)                   | 2 (4.1)                  | 0.095        |
| Kidney injury                         | 9 (5.0)                | 5 (5.0)                  | 1 (3.2)                   | 3 (6.1)                  | 0.901        |
| Others                                | 15 (8.3)               | 10 (9.9)                 | 2 (6.5)                   | 3 (6.1)                  | 0.757        |

(Continued)
Fisher’s exact tests. Cut-off points were presented via receiver operating characteristic (ROC) curves. Risk factors for MACE and FACE were determined with univariate logistic regression and multivariate logistic regression. Odds ratios (OR) with 95% confidence intervals (CI) and the corresponding P-values were calculated for each risk factor. Risk factors for in-hospital maternal death were determined with univariate cox regression and multivariate cox regression. Hazard ratios (HRs) with 95% confidence intervals (CIs) and the corresponding P-values were calculated for each risk factor. Kaplan–Meier survival analysis was used to describe the relative risk of death and the log-rank test was used to compare the survival probability of each group. P-values were considered statistically significant if <0.05 (two-sided test). The variables that had >5% of values missing were excluded. Another missing data imputation was done using the Expectation-Maximization method. All statistical analysis was performed using SPSS 25.0 (IBM Corporation, Armonk, New York, USA).

**Results**

**Patient characteristics**

From January 2013 to December 2018, a total of 60,306 deliveries were performed at the three provincial maternal referral centers and 220 (3.65 per 1,000 births) had PH. Of patients with PH, 186 (84.5%) were admitted to ICU. Five patients were excluded for missing data. In the final analysis, 181 patients were included in this study. Among all the pregnant patients with PH, 49 (27.1%) cases had an sPAP above 70 mmHg, 31 (17.1%) cases had an sPAP between 50 and 70 mmHg, and 101 (55.8%) cases had an sPAP below 50 mmHg. The maternal median age was 32 (27, 35) years and 37% were nulliparous. In more than 65% of patients, the PH diagnosis was made before pregnancy. However, no patients received targeted therapy for PH before or during pregnancy. The median gestational age on admission was 35 (32, 37) weeks, and there were no differences in mild, moderate, and severe PH groups. On admission, the sign of heart failure was presented in more than one-third of the pregnant women. Overall, women with severe PH were associated with higher NYHA cardiac classification compared to those with mild and moderate PH (P < 0.001). It was found that iPH was present in 33 (18.2%) patients, CHD-PH in 83 (45.9%), LHD-PH in 15 (8.3%), and oPH in 50 (27.6%) patients. Further baseline characteristics are presented in Table 1.

**Management and clinical characteristics of patients**

Management of pregnant patients with PH is presented in Table 2. The median gestational age at delivery was 35 (32, 38) weeks. Cesarean section (CS) was performed in 174 patients (96.1%), of which 37 (20.4%) were emergency operations. Only 7 (3.9%) women delivered virginaly. Compared with mild (n = 20, 19.8%) and moderated (n = 6, 19.4%) PH patients, more women with severe PH (n = 24, 49%) received general anesthesia. At ICU admission, compared with mild and moderate PH patients, the patients with sPAP >70 mmHg showed higher sequential organ failure assessment (SOFA) score, Acute Physiology, Age and Chronic Health Evaluation II (APACHE II) score, blood lactate level, D-dimer level, and more PaO2/FiO2 decrease. Further treatments are presented in Table 2.

### Table 1 (Continued)

| Variable                      | Total (n = 181) | Mild PH (n = 101) | Moderate PH (n = 31) | Severe PH (n = 49) | p-value |
|-------------------------------|-----------------|-------------------|----------------------|-------------------|---------|
| **Related diseases (n, %)**   |                 |                   |                      |                   |         |
| iPH                           | 33 (18.2)       | 23 (22.8)         | 4 (12.9)             | 6 (12.2)          | 0.099   |
| CHD-PH                        | 83 (45.9)       | 34 (33.7)         | 14 (45.2)            | 35 (71.4)         | <0.001  |
| Eisenmenger syndrome          | 8 (4.4)         | 0 (0)             | 1 (3.2)              | 7 (14.3)          | <0.001  |
| Left-to-right shunts          | 29 (16.0)       | 11 (10.9)         | 4 (12.9)             | 14 (28.6)         | 0.075   |
| LHD-PH                        | 15 (8.3)        | 9 (8.9)           | 5 (16.1)             | 1 (2.0)           | 0.075   |
| oPH                           | 50 (27.6)       | 35 (34.7)         | 8 (25.8)             | 7 (14.3)          | 0.041   |
| Length of hospital stay, days | 7 (5, 9)        | 7 (5, 9)          | 7 (5, 9)             | 7 (5, 10)         | 0.898   |
| Length of ICU stay, days      | 2 (2, 4)        | 2 (1, 3)          | 2 (2, 3)             | 3.5 (2, 5)        | <0.001  |

**APACHE II score, Acute Physiology, Age and Chronic Health Evaluation II score; BMI, body mass index; CHD-PH, patients with the previous history of congenital heart disease; CRP, C-reactive protein; HELLP syndrome: hemolysis, elevated liver enzymes, and low platelets syndrome; ICU, intensive care unit; iPH, patients with an initial diagnosis of idiopathic pulmonary hypertension before this admission and without any known cause of pulmonary hypertension; LHD-PH, patients with a history of left ventricular systolic dysfunction but not congenital structural abnormality; M, median; MAP, mean arterial pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; oPH, pulmonary hypertension associated with other disease; PA, pulmonary artery; PH, pulmonary hypertension; Q1, the first quartile; Q3, the third quartile; SOFA score, sequential organ failure assessment score; sPAP, systolic pulmonary arterial pressure estimated via echocardiography.**
### TABLE 2  Management of pregnant patients with pulmonary hypertension.

| Variable                                    | Total  
|----------------------------------------------|-------|
|                                              | (n = 181) | Mild PH  
|                                              | (n = 101) | Moderate PH  
|                                              | (n = 31)  | Severe PH  
|                                              | (n = 49)  | p-value |
| Delivery, weeks                              | 35 (32, 38) | 36 (32, 38) | 37 (34, 38) | 34 (31, 37) | 0.185 |
| Mode of delivery (n, %)                      | 7 (3.9) | 2 (2.0) | 1 (3.2) | 4 (8.2) | 0.020 |
| Cesarean section                             | 174 (96.1) | 99 (98.0) | 30 (96.8) | 45 (91.8) | 0.021 |
| Emergency cesarean section                   | 37 (20.4) | 16 (15.8) | 6 (19.4) | 15 (30.6) | 0.232 |
| **Anesthesia (n, %)**                        | 51 (28.2) | 20 (19.8) | 6 (19.4) | 24 (49.0) | 0.002 |
| General                                      | 10 (9.9) | 5 (16.1) | 4 (8.2) | 1.000 |
| Epidual                                      | 1 (1.0) | 0 (0) | 19 (38.8) | 0.003 |
| Spinal                                       | 108 (59.7) | 70 (69.3) | 19 (61.3) | 19 (38.8) | 0.003 |
| Moderate PH                                  | 2 (2.0) | 1 (3.2) | 5 (16.1) | 4 (8.2) | 0.538 |
| Emergency cesarean section                   | 1 (1.0) | 0 (0) | 19 (38.8) | 0.003 |
| **On ICU admission**                         | 51 (28.2) | 20 (19.8) | 6 (19.4) | 24 (49.0) | 0.002 |
| APACHE II score, [M, (Q1, Q3)]              | 5 (3.7) | 4 (3.6) | 5 (3.7) | 6 (4.8) | 0.001 |
| SOFA score, [M, (Q1, Q3)]                   | 1 (1.2) | 1 (1.2) | 1 (1.3) | 2 (1.4) | 0.023 |
| Lactate, mmol/L, [M, (Q1, Q3)]              | 1.2 (1.0, 1.7) | 1.0 (0.9, 1.4) | 1.3 (0.9, 2.0) | 1.5 (1.2, 2.8) | 0.000 |
| NT-proBNP, pg/ml, [M, (Q1, Q3)]             | 451.2 (201.7, 1299.5) | 440.7 (196.6, 1057.8) | 730.1 (208.5, 1457.8) | 548.7 (219.75, 1669.5) | 0.532 |
| cTnI, ng/ml, [M, (Q1, Q3)]                  | 10.7 (6.93, 22.1) | 10.8 (6.9, 19.2) | 9.1 (6.3, 16.1) | 12.6 (5.9, 39.3) | 0.489 |
| PaO2/FiO2 ≤100 (n, %)                       | 13 (7.2) | 1 (1.0) | 1 (3.2) | 11 (22.4) | <0.001 |
| 100–300 (n, %)                               | 109 (60.2) | 66 (65.3) | 17 (54.8) | 26 (53.1) | 0.003 |
| >300 (n, %)                                  | 59 (32.6) | 34 (33.7) | 13 (41.9) | 12 (24.5) | 0.003 |
| Hemoglobin, g/L, [M, (Q1, Q3)]               | 106.0 (94.0, 120.0) | 113.0 (101.0, 119.0) | 111.0 (102.0, 127.0) | 116.0 (105.0, 135.0) | 0.113 |
| Hematocrit, %, [M, (Q1, Q3)]                 | 32.8 (29.4, 35.8) | 35.0 (31.8, 36.9) | 33.8 (32.2, 38.0) | 35.9 (32.9, 40.8) | 0.003 |
| Platelets, ×10^9/L, [M, (Q1, Q3)]            | 177.0 (128.0, 228.0) | 194.0 (147.0, 227.0) | 218.0 (175.0, 281.0) | 178.0 (115.0, 219.0) | 0.222 |
| D-dimer, mg/L, [M, (Q1, Q3)]                 | 3.71 (2.18, 7.72) | 4.3 (2.7, 10.9) | 2.6 (1.8, 4.1) | 3.2 (2.0, 8.3) | 0.033 |
| CRP, mg/L, [M, (Q1, Q3)]                     | 5.63 (1.83, 21.7) | 4.1 (1.5, 18.3) | 16.4 (2.1, 35.5) | 10.1 (3.2, 26.3) | 0.173 |
| Acute kidney injury (n, %)                   | 6 (5.9) | 1 (3.2) | 5 (10.2) | 3 (6.1) | 0.062 |
| Treatment (n, %)                             | 16 (8.8) | 5 (3.0) | 3 (9.7) | 8 (16.3) | 0.001 |
| Inotropic agents                             | 21 (11.6) | 3 (3.0) | 4 (12.9) | 13 (26.5) | <0.001 |
| Vasoconstrictors                             | 121 (66.9) | 72 (71.3) | 22 (71.0) | 27 (55.1) | 0.099 |
| Anticoagulation                              | 2 (1.1) | 0 (0) | 1 (3.2) | 1 (2.0) | 0.195 |
| Targeted PAH therapy                         | 9 (5.0) | 3 (3.0) | 1 (3.2) | 5 (10.2) | 0.187 |
| CRRT                                          | 1 (0.5) | 0 (0) | 0 (0) | 1 (2.0) | 0.440 |
| Fluid balance, ml, [M, (Q1, Q3)]             | −375 (−1321, 210) | −651 (−1686, 105) | −493 (−1058, 231) | −231 (−814, 233) | 0.084 |
| 1st 24 h                                     | −386 (−1202, 140) | −421 (−1406, 270) | −250 (−1249, 55) | −386 (−1104, 97.5) | 0.965 |
| 2nd 24 h                                     | −150 (−735, 480) | −97.5 (−658, 1125) | 32.2 (−590, 384.5) | −211 (−777, 269) | 0.592 |

**TABLE 2 Management of pregnant patients with pulmonary hypertension.**

**Variable**

- **Delivery, weeks**
- **Mode of delivery (n, %)**
- **Anesthesia (n, %)**
- **On ICU admission**
- **Treatment (n, %)**
- **Fluid balance, ml [M, (Q1, Q3)]**

**p-value**

- 0.185
- 0.020
- 0.021
- 0.232
- 0.002
- 0.538
- 0.232
- 0.003
- 0.001
- 0.023
- 0.000
- 0.023
- 0.003
- 0.173
- 0.062
- <0.001
- 0.099
- 0.195
- 0.187
- 0.440
- 0.084
- 0.965
- 0.592

**Note:** APACHE II score, Acute Physiology, Age and Chronic Health Evaluation II score; cTnI, cardiac troponin I; CRP, C-reactive protein; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; M, median; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAH, pulmonary hypertension; PaO2/FiO2, the ratio of arterial oxygen partial pressure to fractional inspired oxygen; Q1, the first quartile; Q3, the third quartile; SOFA score, sequential organ failure assessment score.
Maternal and fetal outcomes

The in-hospital outcomes of these pregnant PH women are shown in Table 3. The MACE occurred in 59 (32.6%) women: in-hospital death in 13 (7.2%), heart failure in 53 (29.3%), and sustained arrhythmia in 7 (3.9%). Compared with patients with sPAP ≤70 mmHg, women with sPAP above 70 mmHg experienced significantly higher MACE (51.0 vs. 25.8%, \( P = 0.001 \)). The related diseases and severity distribution of PH parturients who experienced MACE are shown in Figure 2. The in-hospital survival outcomes of these pregnant PH women are shown in Figure 3. Compared with mild and moderate PH patients, patients with severe PH had a significantly higher mortality rate (22.4%, \( P < 0.001 \)). Of all the 13 in-hospital deaths, 1 died of pulmonary hypertension crisis and 12 died of heart failure. There were two deaths in patients with moderate PH. One patient (sPAP = 53 mmHg) died of valvular thrombosis-induced heart failure, which was due to previous aortic valve replacement, postpartum hemorrhage, and anticoagulant discontinuation. The other patient (sPAP = 70 mmHg) died of a sudden cardiac arrest. In addition, most patients died within 1 week postpartum (3 died within 24 h and 9 died within 24 h to 1 week postpartum), and one woman died 12 days after delivery. Moreover, a total of 168 patients were followed up for at least 1 year after discharge. During the follow-up, 1 patient died of heart failure 116 days after discharge and one patient died of cerebral hemorrhage 110 days after discharge. Both the two patients had sPAP above 70 mmHg.

The FACE occurred in 120 (66.3%) women, including 17 (9.4%) therapeutic abortion, 6 (3.3%) fetal death, 3 (1.7%) neonatal death, 63 (34.8%) prematurity, 9 (5.0%) fetal distress. Although the incidence of FACE in patients with severe PH was slightly higher than that in patients with mild to moderate PH, there was no significant difference (69.4 vs. 65.1%, \( P = 0.724 \)). Further maternal and fetal/neonatal outcomes are presented in Table 3.

Risk factors for maternal and fetal outcomes

The result of univariable logistic and cox regression is presented in Supplementary material 2. The result of multivariable logistic and cox regression is shown in Tables 4, 5. MACE was more likely to occur in patients with higher sPAP, higher NT-BNP level, higher lactate level, higher cTnI level, and lower \( \text{PaO}_2/\text{FiO}_2 \). Under the age of 25, heart failure on admission, acute kidney injury, LHD-PH, emergency

### Table 3: Maternal and fetal/neonatal outcomes of women with PH diagnosed via echocardiography.

| Variable                      | Total       | Mild PH     | Moderate PH | Severe PH   | \( p \)-value |
|-------------------------------|-------------|-------------|-------------|-------------|--------------|
| **Maternal outcome**          |             |             |             |             |              |
| Death (n, %)                  | 13 (7.2)    | 0 (0)       | 2 (6.5)     | 11 (22.4)   | <0.001       |
| During pregnancy (n, %)       | 0 (0)       | 0 (0)       | 0 (0)       | 0 (0)       | 1.000        |
| Postpartum (<24 h) (n, %)    | 3 (1.7)     | 0 (0)       | 0 (0)       | 3 (6.1)     | 0.023        |
| Postpartum (24 h–1 w) (n, %)  | 9 (5.0)     | 0 (0)       | 2 (6.5)     | 7 (14.3)    | <0.001       |
| Postpartum (>1 w, <6 w) (n, %)| 1 (0.6)     | 0 (0)       | 0 (0)       | 1 (2.0)     | 0.439        |
| Sustained arrhythmia (n, %)   | 7 (3.9)     | 1 (1.0)     | 3 (9.7)     | 3 (6.1)     | 0.033        |
| Heart failure (n, %)          | 53 (29.3)   | 23 (22.8)   | 8 (25.8)    | 22 (44.9)   | 0.008        |
| Thromboembolic event (n, %)   | 3 (1.7)     | 1 (1.0)     | 0 (0)       | 2 (4.1)     | 0.255        |
| Postpartum hemorrhage (n, %)  | 8 (4.4)     | 6 (5.9%)    | 1 (3.2)     | 1 (2.0)     | 0.695        |
| MACE (n, %)                   | 59 (32.6)   | 24 (23.8)   | 10 (32.2)   | 25 (51.0)   | 0.001        |
| **Fetal/neonatal outcome**    |             |             |             |             |              |
| Live births (n, %)            | 155 (85.6)  | 88 (87.1)   | 29 (93.5)   | 38 (77.5)   | 0.137        |
| Prematurity (birth <37 w) (n, %)| 108 (59.7)  | 62 (61.4)   | 16 (51.6)   | 30 (61.2)   | 0.598        |
| Therapeutic abortion          | 17 (9.4)    | 8 (7.9)     | 1 (3.2)     | 8 (16.3)    | 0.154        |
| Fetal death (n, %)            | 6 (3.3)     | 4 (4.0)     | 0 (0)       | 2 (4.1)     | 0.727        |
| Pregnancy loss (n, %)         | 23 (12.7)   | 12 (11.9)   | 1 (3.2)     | 10 (20.4)   | 0.087        |
| Low birth weight (n, %)       | 63 (34.8)   | 35 (34.7)   | 10 (32.2)   | 18 (36.7)   | 0.928        |
| Fetal distress (n, %)         | 9 (5.0)     | 6 (5.9)     | 1 (3.2)     | 2 (4.1)     | 1.000        |
| Neonatal malformation (n, %)  | 1 (0.6)     | 0 (0)       | 1 (3.2)     | 0 (0)       | 0.167        |
| Neonatal death (n, %)         | 3 (1.7)     | 2 (2.0)     | 0 (0)       | 1 (2.0)     | 1.000        |
| FACE (n, %)                   | 120 (66.3)  | 69 (68.3)   | 17 (54.8)   | 34 (69.4)   | 0.928        |

FACE, fetal adverse clinical events; MACE, major adverse cardiovascular events; PH, pulmonary hypertension.
cesarean section, and higher APECHE II and SOFA scores were considered possible risk factors for MACE. Patients in whom the FACE occurred had higher BMI, higher NT-proBNP, higher SOFA score, and lower PaO2/FiO2. Hypertension, eclampsia/preeclampsia, CHD-PH, and general anesthesia were all considered possible risk factors for FACE. According to the multivariable logistic regression analysis, the development of MACE was associated with the complication of left heart disease (OR = 4.365, CI:1.306–14.591), and elevated NT-proBNP level (OR = 1.051, CI:1.015–1.088) and sPAP level estimated by echocardiography (OR = 1.021; CI: 1.003–1.040). Combined with eclampsia/preeclampsia was considered to be a risk factor for FACE (OR = 6.713; CI: 1.806, 24.959). Delivery week >32 weeks was proved to be protective in FACE (OR = 0.056, CI: 0.007–0.444). According to the cox regression, in-hospital maternal death was much more likely to happen in patients with higher sPAP estimated by echocardiography (HR = 1.056; CI: 1.029–1.084), higher NT-proBNP level on admission (HR = 1.011; CI: 1.001–1.020) and higher lactate level on ICU admission (HR = 1.135; CI: 1.020–1.263). As presented in the ROC curves (see Supplementary material 3), the cut-off of sPAP, NT-proBNP on admission, and lactate level on ICU admission was 70 mmHg, 1,000 pg/ml, and 2.85 mmol/L, respectively.

**Discussion**

In this retrospective multicenter study, we analyzed clinical characters, complications, treatments, as well as maternal and fetal/neonatal outcomes of 181 pregnant PH women in the past 6 years. The incidence of MACE (32.6%) and FACE (66.3%) remained extremely high despite the continuous progress of treatment in recent years. Pregnant women with LHD-PH, high NT-proBNP levels, and higher sPAP levels were risk factors for the development of MACE. In addition, high sPAP (≥70 mmHg) estimated via echocardiography elevated NT-proBNP (≥1,000 pg/ml) on admission, as well as high lactate level (≥2.85 mmol/L) on ICU admission had a good predictive value for maternal death. Combined with eclampsia/preeclampsia was independently associated with FACE development.

Consistent with previous studies, patients with LHD-PH experienced the most MACE. There were 53.3% (8 out of
LHD-PH patients who experienced MACE, which was much higher than the other three groups (34.9% in CHD-PH patients, 33.3% in iPH patients, and 22.0% in oPH patients). In a European registry of 1,321 pregnant women with cardiac disease, patients with cardiomyopathy, commonly combined with left ventricular dysfunction, had the most adverse cardiac events (9). Different from the systolic and diastolic capacity of right ventricular injury caused by long-lasting increased afterload, LHD-PH often occurred as a consequence of a passive filling pressure of the left heart, which was driven by left ventricular dysfunction and left atrium compliance loss (10, 11). After delivery, uterine contraction and increased blood volume would further aggravate the condition. However, despite the relatively high incidence of adverse events, all of the LHD-PH women survived, and most of them underwent a successful delivery, which was consistent with previous reports (6, 12). The possible reason was that most of the underlying heart diseases were generally monitored and well-controlled before pregnancy, and most of the LHD-PH patients were in the mild to moderate PH group.

Pregnancy with PH has a high risk of death. Compared with the maternal mortality rate (18.3/100,000) in China in 2018, the mortality rate of pregnant patients complicated with PH increased by nearly 400 times in the present study. Similar to our study, higher mortality was also reported in other studies but showed a decreasing trend (1, 13, 14). A meta-analysis including 20 studies and 589 cases reported a pooled maternal mortality of 11.5%. The data from a European registry of 151 pregnant PH women showed a mortality of 3.3% within 1 week postpartum, and 4.6% during 6-month postpartum follow-up (2). In another study of 1,519 patients using the U.S. database data, the in-hospital maternal mortality was 0.8% (6, 15). The authors attributed this relatively lower maternal mortality to collaborative multidisciplinary team management, planned termination of pregnancy before 28 weeks, and preference for spinal or epidural anesthesia. Therapeutic abortion was also found helpful in other researches; however, the mode of delivery and anesthesia remained contentious (16). In this study, we also found that no death occurred in patients who terminated pregnancy before 28 weeks, including patients with severe PH in this study, suggesting that early termination of pregnancy might improve the prognosis of pregnant women with PH, but more real-world studies are warranted.
TABLE 4 Multivariable logistic regression of risk factors for MACE and FACE in pregnant patients with PH diagnosed via echocardiography.

| Variable | Multivariable logistic regression |
|----------|----------------------------------|
|          | OR (95%CI)                        |
| MACE (n = 59, 32.6%) |                                  |
| LDH-Ph | 4.365 (1.306, 14.591)            |
| NT-proBNP | 1.051 (1.015, 1.088)          |
| sPAP | 1.021 (1.003, 1.040)             |
| FACE (n = 120, 66.3%) |                                  |
| Delivery week greater than 32wks | 0.056 (0.007, 0.444) |
| Combined with eclampsia/preeclampsia | 6.713 (1.806, 24.959) |

MACE, major adverse cardiovascular events; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sPAP, systolic pulmonary arterial pressure.

TABLE 5 Multivariable cox regression of risk factors for maternal mortality in pregnant patients with PH.

| Variable | Multivariable cox regression |
|----------|-----------------------------|
|          | HR (95%CI)                  |
| In hospital maternal death (n = 13, 7.2%) |                                 |
| sPAP | 1.056 (1.029–1.084)         |
| NT-proBNP on admission | 1.011 (1.001–1.020) |
| Lactate level on ICU admission | 1.135 (1.020–1.263) |

ICU, intensive care unit; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sPAP, systolic pulmonary arterial pressure.

Although invasive hemodynamic measurements are still the gold standard for PH diagnosis, a detailed echocardiographic assessment of pulmonary artery pressure could help to identify patients at risk of PH. Accumulating evidence suggested a correlation between non-invasive and invasive data, but the reported results were not completely consistent (17, 18). For an individual patient, significant overestimation and underestimation might occur. Recent guidelines have suggested that although echocardiography could not provide a definitive diagnosis, it was of great significance in determining the probability of PH being present (19). In addition, for pregnant women with confirmed or moderate to severe PH, echocardiography might be more suitable for dynamic prediction and follow-up because of its non-invasive and convenient. Consistent with recent research (20), the level of sPAP measured by echocardiography was closely associated with mortality and morbidity of postpartum adverse events in pregnant PH women in our study. Furthermore, the optimal cut-off value of sPAP for predicting mortality was 70 mm Hg, which yielded sensitivity and specificity of 88.9 and 71.1%, respectively.

In this study, we found that pregnant PH women with high levels of NT-proBNP had higher mortality and more cardiac adverse events. NT-proBNP levels have also been included in the multiparametric risk assessment approach for PH outlined in PH guidelines (3, 21). In PH patients, NT-proBNP was secreted by the ventricular myocardium in response to transmural pressure, volume overload as well as hypoxia (22). As demonstrated in a previous study including PH patients both newly diagnosed and receiving long-term treatment, change in NT-proBNP level was correlated to the changes in right ventricular function (23). However, data supporting the use of NT-proBNP risk thresholds in assessing pregnancy risk in PH are limited and inconsistent. Further studies are required to confirm the prospective use of NT-proBNP in this field.

We noticed a high FACE incidence rate of 66.3% in our study. Compared with a recent meta-analysis that reviewed 589 parturients and 610 pregnancies in 20 studies, there are similar pregnancy loss rate (12.7 vs. 12.6%) and a higher prematurity rate (59.7 vs. 51.7%) in this study (16). Planned early delivery was widely applied to avoid adverse events in our study, which was a possible reason for this high prematurity rate. In our study, PH combined with eclampsia/preeclampsia was associated with FACE. One explanation for poor fetal outcomes of PH patients was limited placental development due to decreased cardiac output (2). Placental disease due to vascular endothelial injury was also recognized as the main cause of fetal restriction and stillbirth in eclampsia/preeclampsia. As reported, women with PH were more likely to experience eclampsia, which was a risk factor for both maternal and fetal adverse events (6, 24). Furthermore, pulmonary artery pressure would significantly increase in the third trimester, and most of the patients with severe PH had NYHA class decline by 1 or 2 (25). Considering maternal and fetal safety, despite the patients’ strong desire of continuing pregnancy, most of them were advised to terminate the pregnancy early. The specific influence of PH on placental development remained unclear. Further research on fetal outcomes was still needed.

The major limitation of the study was related to its retrospective nature. In this study, all data were extracted from the electronic medical system, and some of the data were incomplete or unavailable. In addition, the diagnosis of PH was not made with a right heart catheterization. It is inevitable to overestimate or underestimate the value of sPAP in an individual patient leading to misdiagnosis and inappropriate treatment. The interpretation of our data must take into account the limitations of echocardiography in the diagnosis of PH. Thus, all conclusions must be drawn with caution.

In conclusion, maternal mortality remained high despite advanced treatment, and the incidence of MACE and FACE was also very high in this multicenter data set of critically ill
pregnant women with PH in China. PH patients with left heart disease, increased sPAP estimated by echocardiography, and elevated NT-proBNP are at high risk of cardiac adverse events and should receive closer medical monitoring. If necessary, planned early delivery should be considered to avoid sudden deterioration of cardiac function. However, further studies are warranted to identify subsets of women with PH at lower pregnant risks and seek more effective therapy to improve pregnancy outcomes.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Medical Ethics Committee of Provincial Hospital Affiliated to Shandong University. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

Author contributions

YC and MM contributed to conception and design of the study. GQ, XY, HZ, FZ, and TW contributed to data acquisition and outcome measure. LZ and YC performed the statistical analysis. LZ wrote the first draft of the manuscript. YC, MM, and JS revised the manuscript critically. All authors contributed to manuscript revision, read, and approved the submitted version.

Funding

The work was supported by Foster fund of the Second Hospital, Cheeloo College of Medicine, Shandong University (2022YP73), Clinical Medical Science and Technology Innovation Project of Jinan (202134023), and Shandong traditional Chinese Medicine Science and Technology Project (2021M184).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.872833/full#supplementary-material

References

1. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. *J Am Coll Cardiol.* (1998) 31:1650–7. doi: 10.1016/S0735-1097(98)00162-4

2. Slivka K, van Hagen IM, Buda W, Swan L, Sinagra G, Caruana M, et al. Pulmonary hypertension and pregnancy outcomes: data from the registry of pregnancy and cardiac disease (Ropac) of the European society of cardiology. *Eur J Heart Fail.* (2016) 18:1119–28. doi: 10.1002/ejhf.594

3. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 Esc/Ers Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (Eusc) and the European Respiratory Society (Ers): endorsed by: association for European pediatric and congenital cardiology (Aepc), international society for heart and lung transplantation (Isht). *Eur Respir J.* (2015) 46:903–75. doi: 10.1183/13993003.01032-2015

4. Lima FV, Yang J, Xu J, Stergiopoulous K. National trends and in-hospital outcomes in pregnant women with heart disease in the United States. *Am J Cardiol.* (2017) 119:1694–700. doi: 10.1016/j.amjcard.2017.02.003

5. Opotowsky AR, Siddiqi OK, Webb GD. Trends in Hospitalizations for Adults with Congenital Heart Disease in the US. *J Am Coll Cardiol.* (2009) 54:460–7. doi: 10.1016/j.jacc.2009.04.037

6. Thomas E, Yang J, Xu J, Lima FV, Stergiopoulous K. Pulmonary hypertension and pregnancy outcomes: insights from the national inpatient sample. *J Am Heart Assoc.* (2017) 6:144. doi: 10.1161/JAHA.117.006144

7. Lima FV, Parikh PB, Zhu J, Yang J, Stergiopoulous K. Association of cardiomyopathy with adverse cardiac events in pregnant women at the time of delivery. *JACC Heart Fail.* (2015) 3:257–66. doi: 10.1016/j.jchf.2014.10.008

8. Owens A, Yang J, Nie L, Lima F, Avila C, Stergiopoulous K. Neonatal and maternal outcomes in pregnant women with cardiac disease. *J Am Heart Assoc.* (2018) 7:e009395. doi: 10.1161/JAHA.118.009395

9. Roos-Hesselink JW, Ruys TP, Stein JI, Thilen U, Webb GD, Niwa K, et al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European society of cardiology. *Eur Heart J.* (2013) 34:657–65. doi: 10.1093/eurheartj/eth270
10. Vachiery JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. *Eur Respir J.* (2019) 53:2014. doi: 10.1183/13993003.01897-2018

11. Al-Omary MS, Sugito S, Boyle AJ, Sverzlov AL, Collins NJ. Pulmonary hypertension due to left heart disease: diagnosis, pathophysiology, and therapy. *Hypertension.* (2020) 75:1397–408. doi: 10.1161/HYPERTENSIONAHA.119.14330

12. Shotan A, Roos-Hesseling I, Baris L, Goland S, Yekel Y, Elkayam U. Cardiomyopathy and pregnancy: considerations for women with severely reduced left ventricular dysfunction. *Can J Cardiol.* (2021) 37:2067–75. doi: 10.1016/j.cjca.2021.09.023

13. Bedard E, Dimopoulos K, Gatzoulis MA. Has There been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? *Eur Heart J.* (2009) 30:236–65. doi: 10.1093/eurheartj ehz597

14. Liang J, Li X, Kang C, Wang Y, Kulikoff XR, Coates MM, et al. Maternal mortality ratios in 2,852 Chinese counties, 1996–2015, and achievement of millennium development goal 5 in china: a subnational analysis of the global burden of disease study 2016. *Lancet.* (2019) 393:241–52. doi: 10.1016/S0140-6736(18)31712-4

15. Zhao H, Zhang H, Xu X, Wang Y, Gu H, Zhang J. Risk factors for perinatal cardiac complications in pregnancy with pulmonary hypertension. *Pregnancy Hypertens.* (2018) 12:207–13. doi: 10.1016/j.preghy.2017.09.001

16. Jha N, Jha AK, Mishra SK, Sagli H. Pulmonary hypertension and pregnancy outcomes: systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol.* (2020) 253:108–16. doi: 10.1016/j.ejogr.2020.08.028

17. Greiner S, Jud A, Aurich M, Hess A, Hillbel T, Hardt S, et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by doppler echocardiography compared to right heart catheterization: analysis in a large patient population. *J Am Heart Assoc.* (2014) 3:1103. doi: 10.1161/JAHA.114.001103

18. D’Alto M, Bossone E, Opotowsky AR, Ghio S, Rudski LG, Naeije R. Strengths and weaknesses of echocardiography for the diagnosis of pulmonary hypertension. *Int J Cardiol.* (2018) 263:177–83. doi: 10.1016/j.ijcard.2018.04.024

19. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, et al. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the british society of echocardiography. *Echo Res Pract.* (2018) 5:G11–24. doi: 10.1530/ERP-17-0071

20. Lai W, Ding Y, Wen L. Long-Term Outcomes of Pregnant Women with Pulmonary Hypertension diagnosed by echocardiography: a retrospective cohort study in a single center from China. *Pulm Circ.* (2021) 11:2045894020966876. doi: 10.1177/2045894020966876

21. Bouchly A, Weatherald J, Savale J, Jais X, Cottin V, Prevot G, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *Eur Respir J.* (2017) 50:1700889. doi: 10.1183/13993003.00889-2017

22. Lewis RA, Durrington C, Condliffe R, Kiely DG. Bnp/Nt-Probnp in pulmonary arterial hypertension: time for point-of-care testing? *Eur Respir Rev.* (2020) 29:156. doi: 10.1183/16000617.0009-2020

23. Gan CT, McCann GP, Marcus JT, van Wolferen SA, Twisk JW, Boonstra A, et al. Nt-Probnp reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J.* (2006) 28:1190–4. doi: 10.1183/09031936.00016006

24. Fishel Bartal M, Sibai BM. Eclampsia in the 21st Century. *Am J Obstet Gynecol.* (2020) 226:51237–57. doi: 10.1016/j.ajog.2020.09.037

25. Katsuragi S, Yamanaka K, Neki R, Kamiya C, Sasaki Y, Osato K, et al. Maternal outcome in pregnancy complicated with pulmonary arterial hypertension. *Circ J.* (2012) 76:2249–54. doi: 10.1253/circj.CJ-12-0235